참여 물질
| 역할 | 이름 | HCID | 투입량 |
|---|
| 반응물 | 4-bromo-N,N-dimethylbenzamide | HCID 140389 | — |
| 반응물 | HCID 178418219 | HCID 178418219 | — |
| 시약 | Cesium carbonate | HCID 10796 | — |
| 촉매 | 2-(Dicyclohexylphosphino)biphenyl | HCID 2734216 | — |
| 촉매 | Palladium (II) acetate | HCID 4144353 | — |
| 용매 | 1,4-Dioxane | HCID 31275 | — |
| 생성물 | HCID 118717960 | HCID 118717960 | 40.91% |
반응 단계
8-(4-fluorophenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridin-2-amine (101 mg, 0.43 mmol), 4-bromo-N,N-dimethylbenzamide (100 mg, 0.44 mmol), Cesium carbonate (211 mg, 0.65 mmol), Palladium(II) acetate (9.8 mg, 0.04 mmol) and 2-(Dicyclohexylphosphino)biphenyl (15.8 mg, 0.05 mmol) were added to a microwave vial. The vial was capped and flushed with nitrogen. Dioxane (2.5 mL) was added and the vial was flushed with additional nitrogen before it was irradiated in a microwave reactor at 120 °C for 1.5 h. The reaction mixture was diluted with dichloromethane and filtered through a pad of diatomaceous earth. The pad was rinced repeatedly with dichloromethane, then the solvents were removed _in vacuo_. Handed over to the preparative chromatography group for purification (see attached report). The desired fractions were pooled and concentrated _in vacuo_. The residue was partitioned between water and dichloromethane (x1), the organic layer was passed through a phase separator and concentrated _in vacuo_. The residue was redissolved in acetonitrile and water was added. Freeze-dried over weekend to give 4-(8-(4-fluorophenyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[1,5-a]pyridin-2-ylamino)-N,N-dimethylbenzamide (67.5 mg, 40.9 %).
출처 및 근거
| 출처 데이터셋 | 750 AstraZeneca ELN dataset |
|---|
| ORD ID | ord-700c6d20880044119041252f015d9cec |
|---|
| 출처 메모 | 750 AstraZeneca ELN dataset |
|---|